Accepted for Publication: January 23, 2019.
Corresponding Author: Roger S. McIntyre, MD, Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst St, Toronto, ON M5T 2S8, Canada (roger.mcintyre@uhn.ca).
Published Online: May 8, 2019. doi:10.1001/jamapsychiatry.2019.0779
Author Contributions: Dr McIntyre had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: McIntyre, Lee, Shekotikhina, Rosenblat, Brietzke, Soczynska, Suppes, Mansur.
Acquisition, analysis, or interpretation of data: McIntyre, Subramaniapillai, Lee, Pan, Carmona, Shekotikhina, Rosenblat, Brietzke, Cosgrove, Miller, Fischer, Kramer, Dunlap, Suppes, Mansur.
Drafting of the manuscript: McIntyre, Subramaniapillai, Lee, Pan, Shekotikhina, Soczynska, Miller, Fischer, Suppes, Mansur.
Critical revision of the manuscript for important intellectual content: McIntyre, Subramaniapillai, Lee, Pan, Carmona, Shekotikhina, Rosenblat, Brietzke, Soczynska, Cosgrove, Kramer, Dunlap, Suppes, Mansur.
Statistical analysis: McIntyre, Lee, Pan, Shekotikhina, Rosenblat, Brietzke, Mansur.
Obtained funding: McIntyre, Soczynska.
Administrative, technical, or material support: McIntyre, Subramaniapillai, Lee, Pan, Carmona, Shekotikhina, Rosenblat, Brietzke, Soczynska, Cosgrove, Miller, Fischer, Dunlap, Mansur.
Supervision: McIntyre, Subramaniapillai, Shekotikhina, Rosenblat, Cosgrove, Suppes.
Conflict of Interest Disclosures: Dr McIntyre reported receiving grants from Stanley Medical Research Institute during the conduct of the study; receiving grants from the Canadian Institutes of Health Research/Global Alliance for Chronic Diseases/Chinese National Natural Research Foundation outside the submitted work; and receiving speaking/consultation fees from Lundbeck, Janssen, Shire, Purdue, Pfizer, Otsuka, Allergan, Takeda, Neurocrine, Sunovion, and Minerva outside the submitted work. Ms Subramaniapillai reported receiving grants from Stanley Medical Research Institute during the conduct of the study. Dr Brietzke reported receiving personal fees from Daiichi Sankyo and receiving grants from Conselho Nacional de Desenvolvimento Cientifico e Tecnológico, Sãn Paulo Research Foundation, Coordenação de Aperfeicoamento de Pessoal de Nível Superior (CAPES), and L’Oreal for Women in Science Award outside the submitted work. Dr Suppes reported receiving grants from Stanley Medical Research Institute during the conduct of the study and from the National Institute on Drug Abuse, the National Institutes of Health, National Institute of Mental Health, Palo Alto Health Sciences, Pathway Genomics, and VA Cooperative Studies Program; receiving personal and nonfinancial support from CMEology, Global Medical Education, and Sunovion Pharmaceuticals Inc; and receiving personal fees from Allergan Inc, Hogrefe Publishing, Jones and Bartlett, Medscape Education, and UpToDate. Dr Miller reported receiving grants from Stanley Medical Research Institute during the conduct of the study and from Merck & Co and Sunovion outside the submitted work. No other disclosures were reported.
Funding/Support: This study was supported by grant 13T-012 from the Stanley Medical Research Institute.
Role of the Funder/Sponsor: The Stanley Medical Research Institute had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Data Sharing Statement: See Supplement 3.
3.Subramaniapillai
M, Carmona
NE, Rong
C, McIntyre
RS. Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders.
Dialogues Clin Neurosci. 2017;19(1):27-36.
PubMedGoogle Scholar 5.Aas
M, Dieset
I, Hope
S,
et al. Childhood maltreatment severity is associated with elevated C-reactive protein and body mass index in adults with schizophrenia and bipolar diagnoses.
Brain Behav Immun. 2017;65:342-349. doi:
10.1016/j.bbi.2017.06.005PubMedGoogle ScholarCrossref 7.Kappelmann
N, Lewis
G, Dantzer
R, Jones
PB, Khandaker
GM. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions.
Mol Psychiatry. 2018;23(2):335-343. doi:
10.1038/mp.2016.167PubMedGoogle ScholarCrossref 8.Raison
CL, Rutherford
RE, Woolwine
BJ,
et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.
JAMA Psychiatry. 2013;70(1):31-41. doi:
10.1001/2013.jamapsychiatry.4PubMedGoogle ScholarCrossref 9.Felger
JC, Haroon
E, Patel
TA,
et al. What does plasma CRP tell us about peripheral and central inflammation in depression? [published online June 12, 2018].
Mol Psychiatry.
PubMedGoogle Scholar 13.Cheng
AY; Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada: introduction.
Can J Diabetes. 2013;37(suppl 1):S1-S3. doi:
10.1016/j.jcjd.2013.01.009PubMedGoogle ScholarCrossref 15.Etain
B, Lajnef
M, Brichant-Petitjean
C,
et al. Childhood trauma and mixed episodes are associated with poor response to lithium in bipolar disorders.
Acta Psychiatr Scand. 2017;135(4):319-327. doi:
10.1111/acps.12684PubMedGoogle ScholarCrossref 19.Cohen-Woods
S, Fisher
HL, Ahmetspahic
D,
et al. Interaction between childhood maltreatment on immunogenetic risk in depression: discovery and replication in clinical case-control samples.
Brain Behav Immun. 2018;67:203-210. doi:
10.1016/j.bbi.2017.08.023PubMedGoogle ScholarCrossref 20.Baumeister
D, Akhtar
R, Ciufolini
S, Pariante
CM, Mondelli
V. Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-α.
Mol Psychiatry. 2016;21(5):642-649. doi:
10.1038/mp.2015.67PubMedGoogle ScholarCrossref 28.Goldstein
BI, Carnethon
MR, Matthews
KA,
et al; American Heart Association Atherosclerosis; Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young. Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American Heart Association.
Circulation. 2015;132(10):965-986. doi:
10.1161/CIR.0000000000000229PubMedGoogle ScholarCrossref 30.Köhler
CA, Freitas
TH, Stubbs
B,
et al. Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis.
Mol Neurobiol. 2018; 55(5):4195-4206.
PubMedGoogle Scholar 31.Marrie
RA, Walld
R, Bolton
JM,
et al; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease. Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease.
Epidemiol Psychiatr Sci. 2017:1-10. doi:
10.1017/S2045796017000579PubMedGoogle Scholar 32.Leighton
SP, Nerurkar
L, Krishnadas
R, Johnman
C, Graham
GJ, Cavanagh
J. Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis.
Mol Psychiatry. 2018;23(1):48-58. doi:
10.1038/mp.2017.205PubMedGoogle ScholarCrossref